VEDOLIZUMAB AS TREATMENT FOR COMMON VARIABLE IMMUNE DEFICIENCY (CVID): A CASE SERIES AND BRIEF REVIEW OF THE LITERATURE

Common variable immunodeficiency (CVID) is the most common symptomatic immunodeficiency, frequently presenting as recurrent upper respiratory infections. A portion of these patients develop non-specific gastrointestinal symptoms with a smaller subset developing CVID enteropathy, characterized by chronic diarrhea with absence of plasma cells and aggregates of T cells on intestinal pathology. We describe two cases of steroid refractory CVID enteropathy who were started on Vedolizumab (VDZ) with clinical remission.

This entry was posted in News. Bookmark the permalink.